New hope for aggressive breast cancer: precision combo trial targets tough subtype
NCT ID NCT05806060
First seen Feb 28, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This study tests whether adding the drug VEGFR BP102 to standard chemotherapy helps people with a specific subtype of advanced triple-negative breast cancer (called BLIS) live longer without their cancer growing. About 134 participants who have not had prior treatment for metastatic disease will receive either the combination or chemotherapy alone. The main goal is to see if the combination delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast cancer institute of Fudan University Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.